Mark J. Enyedy - May 20, 2022 Form 4 Insider Report for ImmunoGen, Inc. (IMGN)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Stock symbol
IMGN
Transactions as of
May 20, 2022
Transactions value $
$0
Form type
4
Date filed
12/27/2022, 04:16 PM
Previous filing
Feb 8, 2022
Next filing
Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Award $0 +394K $0.00 394K May 20, 2022 Common Stock 394K $4.55 Direct F1
transaction IMGN Stock Option (Right to Buy) Award $0 +788K +200% $0.00 1.18M Nov 14, 2022 Common Stock 788K $4.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
F2 On February 7, 2020, the reporting person was granted an option to purchase 1,575,000 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.